Endometrial cancer is one of the tumor types in which either chromosomal instability (CIN) or microsatellite instability (MSI) may occur. It is known to possess mutations frequently in the Ras-PI3K (phosphatidylinositol 3 0 -kinase) pathway. We performed a comprehensive genomic survey in 31 endometrial carcinomas with paired DNA for chromosomal imbalances (25 by the 50K and 6 by the 250K single-nucleotide polymorphism (SNP) array), and screened 25 of the 31 samples for MSI status and mutational status in the Ras-PI3K pathway genes. We detected five or more copy number changes (classified as CIN-extensive) in 9 (29%), 1 to 4 changes (CINintermediate) in 17 (55%) and no changes (CIN-negative) in 5 (16%) tumors. Positive MSI was less common in CIN-extensive tumors (14%), compared with CIN-intermediate/negative tumors (50%), and multivariate analysis showed that CIN-extensive is an independent poor prognostic factor. SNP array analysis unveiled copy number neutral LOH at 54 loci in 13 tumors (42%), including four at the locus of PTEN. In addition to eight (26%) tumors with PTEN deletions, we detected chromosomal imbalances of NF1, K-Ras and PIK3CA in four (13%), four (13%) and six (19%) tumors, respectively. In all, 7 of the 9 CIN-extensive tumors harbor deletions in the loci of PTEN and/or NF1, whereas all the 10 MSI-positive tumors possess PTEN, PIK3CA and/or K-Ras mutations. Our results showed that genomic alterations in the Ras-PI3K pathway are remarkably widespread in endometrial carcinomas, regardless of the type of genomic instability, and suggest that the degree of CIN is a useful biomarker for prognosis in endometrial carcinomas.
Introduction
Genomic alterations, such as DNA sequence changes, genomic instability and epigenetic gene silencing, cooperate to develop and progress human malignancies. Understanding the molecular basis of cancer has now become feasible through the application of genome analysis technologies, as in a project started by The Cancer Genome Atlas (Cancer Genome Atlas Research Network, 2008) .
Endometrial cancer is the fourth most frequent cancer in women and its incidence is increasing (Parkin, 2001) . There are two different pathogenetic types of endometrial carcinomas: estrogen-dependent type I and estrogen-independent type II (Ryan et al., 2005; Doll et al., 2008) . Approximately, 80% of endometrial carcinomas are endometrioid adenocarcinomas, generally considered as type I tumors. Type II is composed of high-grade tumors (such as serous adenocarcinomas or clear cell carcinomas) with aggressive behavior. Even among type I tumors, recurrent tumors respond limitedly to systemic therapy and the prognosis is very poor. Microsatellite instability (MSI) is associated with mutator phenotype, and is reported approximately at 15-20% in endometrial and colorectal cancer (Atkin, 2001; Woerner et al., 2003) . MSI in endometrial cancer is much more frequent in type I endometrioid adenocarcinomas than in type II tumors (Tashiro et al., 1997; An et al., 2004) . Chromosomal instability (CIN) is measured by the number of chromosomal copy alterations within entire tumor genomes, and the CIN phenotypes can be classified according to the level of alterations, such as CIN-high, CIN-low and CIN-very low (Rowan et al., 2005; Weber et al., 2007; Geigl et al., 2008) . CIN is inversely correlated with MSI in colorectal cancer (Choi et al., 2002; Grady, 2004) ; however, the relationship between CIN and MSI and its prognostic effect in type I endometrioid adenocarcinomas is still controversial (Hirasawa et al., 2003; Arabi et al., 2009) . We especially focused on endometrioid adenocarcinomas to clarify whether the status of genomic instability, determined by CIN and MSI analyses, is associated with morphologically indistinguishable tumor aggressiveness.
Copy number neutral (CNN) LOH is a type of genomic alteration caused by the loss of one allele and gain of the opposite allele. Recently, single-nucleotide polymorphism (SNP) arrays, which could provide allelespecific copy number information, have been applied to detect segmental uniparental structures (Fitzgibbon et al., 2005; Teh et al., 2005; Midorikawa et al., 2006) . Somatic CNN LOH has been increasingly recognized as a common molecular defect in various types of cancer. In addition, improvement of resolution by SNP arrays is also useful in identifying microdeletions, including homozygous deletions (HDs) (Komura et al., 2006; Gorringe et al., 2007) . SNP array analyses have unveiled that regions surrounding various tumor suppressor genes (such as CDKN2A, RB1, TP53, BRCA1, BRCA2, WT1, CEBPA, RUNX1 and NF1) frequently show CNN LOH in many types of tumors (Fitzgibbon et al., 2005; Raghavan et al., 2005; Flotho et al., 2007; Walsh et al., 2008) . Recent studies also indicate that CNN LOH regions may carry activated oncogenes, such as mutated JAK2, HRAS and NRAS (Kralovics et al., 2005; Kratz et al., 2007; Dunbar et al., 2008) . Thus, SNP array is a useful methodology to identify novel genomic alterations in specific genes and pathways.
The phosphatidylinositol 3 0 -kinases (PI3Ks) are widely expressed lipid kinases that catalyze the production of the second messenger phosphatidylinositol 3,4, 5-triphosphate, which activates a wide range of downstream targets, including Akt (Stokoe et al., 1997) . Ras-PI3K signaling is activated through various genetic alterations, such as mutations in Ras, PTEN, EGFR, PIK3CA and AKT1 (Vogelstein et al., 1988; Li et al., 1997; Lynch et al., 2004; Samuels et al., 2004; Carpten et al., 2007) , and amplifications in ERBB2, AKT2 and PIK3CA (Slamon et al., 1989; Cheng et al., 1992; Shayesteh et al., 1999) . In endometrial cancer, high prevalence of mutations of the genes in the Ras-PI3K pathway is reported, including K-Ras, PTEN and PIK3CA (Enomoto et al., 1991; Kong et al., 1997; Oda et al., 2005) . We reported that more than 70% of endometrial carcinomas contain one or more mutations in the Ras-PI3K pathway (Oda et al., 2008) . However, the role of chromosomal imbalances in this pathway is not fully understood. Various kinds of inhibitors targeting the PI3K pathway have been developed and are now under clinical trials (Kong and Yamori, 2008; Maira et al., 2009) . Detailed analysis of genomic alterations in this pathway might clarify the possibility of these molecular targeted therapies in endometrial carcinomas.
In this study, we attempted to comprehensively figure out genomic alterations in endometrial carcinomas. First, we classified endometrial carcinomas into three subgroups according to the CIN status, and found an inverse trend between the high degree of CIN (CINextensive) and positive MSI. Second, we show that CINextensive is an independent poor prognostic predictor in endometrial carcinomas. Third, we focused on the genes involved in the Ras-PI3K pathway for mutations, CNN LOH, HD and other chromosomal imbalances and clarified that genomic alterations associated with the Ras-PI3K pathway are exceedingly widespread in endometrial carcinomas.
Results

Chromosomal gains, losses, CNN LOH and HDs in endometrial carcinomas
As endometrioid adenocarcinoma is the most common histological type showing a high ratio of MSI, we specifically focused on endometrioid adenocarcinomas in this study. We evaluated chromosomal imbalances in a total of 31 endometrioid adenocarcinomas with paired DNA (tumor and normal) by SNP arrays (25 samples on the Affymetrix 50K array and 6 on the 250K array). Chromosomal imbalances with one or more loci were detected in 26 (84%) out of 31 tumors. Gains on chromosome arms were observed on 1q (29%), 2p (10%), 7q (13%), 8p (10%), 8q (19%), 10p (10%), 10q (13%), 12p (16%), 12q (16%), 17q (10%), 20p (13%) and 20q (10%). LOH was detected on 1p (19%), 1q (10%), 2q (13%), 5q (13%), 6q (19%), 9p (16%), 9q (16%), 10q (29%), 16q (19%), 17p (16%) and 22p (10%) (Figure 1 and Supplementary Table 2 ). The regions of these gains and losses were compatible with the reports by comparative genomic hybridization (CGH) (Suehiro et al., 2000; Micci et al., 2004; Levan et al., 2006) . CNN LOH involves allelic changes, including hemizygous deletion with a gain of the opposite allele. In addition to chromosomal gains (16/31; 52%) and LOH (19/31; 61%), we detected CNN LOH in 13 samples (42%) at 54 regions (Table 1 ). All these CNN LOH are somatic events, as these regions in the tumors were identified by retention of heterozygsity in the paired germline DNA. In addition, we assessed known copy number variations (CNVs) from the Database of Genomic Variants v8 (http://projects.tcag.ca/variation/), and confirmed that all of these 54 CNN LOH included non-CNV regions. The regions of CNN LOH include 8q and 10q, at which copy number gains are frequently detected in endometrial carcinomas. Five of the 54 CNN LOH (9%) occur in the whole arm of each chromosome (1p, 1q, 6p, 18p and 18q). The minimal CNN LOH region in 51 out of the 54 was more than 100 kb, and the other three regions with o100 kb were detected in both the 50K and the 250K SNP array ( Table 1 ), suggesting that the 50K SNP probes distinguish CNN LOH at a comparable level with the 250K probes. We found that the CNN LOH regions frequently include the loci of several well-known tumor suppressor genes, such as CDKN2A (9p21.3), PTEN (10q23.3) and TP53 (17p13.1).
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We detected five HD candidate regions in three samples. One of the five regions (6q21.2) was located in the vicinity of a known CNV. Genome imbalance map (GIM) algorithm using the control DNA in this sample with the other from unrelated individuals revealed hemizygous loss at the surrounding region in the germline DNA, suggesting that this locus is not somatic HD. The other four HD regions on 9p21.3, 10q23.3, 11p15.1 and 17q11.21 did not match with any known CNVs and included CDKN2A, CDKN2B, ELAVL2, PTEN, NELL1, IDH3GL and NF1 genes. All these regions were o4.2 Mb and were included in the LOH regions (Figure 1 and Supplementary Table 3) .
SNP array genotyping distinguishes three clusters according to the degree of CIN As the number of copy alterations is significantly different in each tumor, we further divided the CINpositive tumors into CIN-extensive and CIN-intermedi- Figure 1 Overview of genomic imbalance in endometrial carcinomas. SNP array was performed in 31 clinical samples with paired tumor DNA and normal DNA, using a human mapping 50K or 250K Array. Samples are categorized according to the level of chromosomal instability (CIN) as described in the text; CIN-extensive (Ext) with five or more copy number changes, CIN-intermediate (Int) with 1-4 copy number changes, and CIN-negative (N) without any copy number changes.
Genome-wide SNP arrays in endometrial carcinomas S Murayama-Hosokawa et al Figure 2 SNP array 'karyograms' (50K) of representative tumors. In each graph, the top shows the total copy number and the bottom shows the allele-specific copy number. CIN status is classified according to the number of loci with chromosomal imbalances. Table 4 ). Presence of CNN LOH also does not have any significant associations in these factors (data not shown). MSI-high was correlated with vascular invasion (P ¼ 0.049), and shows a tendency toward unfavorable clinicopathological features, such as deep myometrial invasion and old age (Supplementary Table 5 ).
CIN-extensive is a poor prognostic factor in endometrial carcinomas By Kaplan-Meier analysis, MSI-high showed a trend to be a favorable prognostic factor (P ¼ 0.069) (Supplementary Figure 2a) . Next, we analyzed 50K SNP array in the other 11 endometrial carcinomas using tumor DNA, in addition to the 31 tumors. In 42 tumors, the ratio of CIN-extensive, -intermediate and -negative is 26% (11/42), 52% (22/42) and 21% (9/42), respectively. Kaplan-Meier analysis revealed that CIN-extensive was a significant marker of poor prognosis (P ¼ 0.0034 by log-rank test, Figure 3) . A worse prognosis of CINextensive, compared with CIN-intermediate (P ¼ 0.0033, Supplementary Figure 2b) , suggests that not only the existence but also the degree of CIN is important in endometrial tumorigenesis. Stage III-IV and histological grade (grade 2 or 3) were also poor prognostic factors by univariate analysis (Table 3) . Subsequently, multivariate analysis was conducted using these three poor prognostic factors. Only CIN-extensive was found to be a significant and independent predictor for poor survival (Table 3) .
Frequent CNN LOH with homozygous PTEN mutations in endometrial carcinomas
In SNP array analysis, we detected deletions of PTEN locus in 8 out of 31 (26%) tumors: one with HD, four with CNN LOH (marked with an asterisk in Table 1 ) and three with LOH without gain of the opposite allele. We also evaluated PTEN mutations and detected the mutations in 16 of 22 (73%) tumors. Taken together, we found three patterns of biallelic PTEN alterations in a total of eight tumors (36%): three tumors with CNN LOH and a mutation, four with two mutations and one with HD (Supplementary Table 6 ). Monoallelic PTEN alterations were observed in 11 tumors (50%): nine with a mutation, one with CNN LOH and one with LOH (Supplementary Table 6 ). Only three (14%) tumors showed no genomic alterations in PTEN. In our previous study, we did not observe any PTEN hypermethylation in 53 endometrial carcinomas (Shoji et al., 2009) .
MSS tumors frequently possess chromosomal imbalances in genes associated with the Ras-PI3K pathway MSI is thought to correlate with mutator phenotype, and is reported to possess PTEN mutations more frequently than MSS in endometrial carcinomas. Indeed, all the MSI-high tumors possess PTEN mutations, whereas 6 of 12 MSS tumors (50%) possess PTEN mutations (P ¼ 0.015) (Supplementary Table 6 ). On the other hand, we found that six out of seven (87%) tumors with chromosomal imbalances of PTEN were MSS, suggesting that chromosomal imbalances have significant roles in disrupting PTEN function in MSS tumors.
Next, we analyzed genomic alterations of the other Ras-PI3K-related genes (NF1, K-Ras and PIK3CA). We found mutations of K-Ras and PIK3CA in 2 (9%) and 6 (27%) out of 22 tumors, respectively. In addition to one HD (4%) and two LOH (8%) at the NF1 locus, we found gains at the loci of PIK3CA (3q26.3) in four (16%) tumors and K-Ras (12p12.1) in four (16%) tumors. CNN LOH at the loci of PIK3CA was observed in two (8%) tumors, including one with a PIK3CA mutation. 
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We summarized the data of genomic alterations in the four genes (PTEN, PIK3CA, K-Ras and NF1) of the Ras-PI3K pathway (Table 4 ). In total, six out of the seven CIN-extensive tumors show deletion(s) in PTEN and/or NF1. Although the biological functions of copy number gains in K-Ras and PIK3CA are to be elucidated, all the seven CIN-extensive tumors show chromosomal imbalances in the loci of genes associated with the Ras-PI3K pathway, whereas 5 of the 14 CINintermediate tumors (36%) show such imbalances (P ¼ 0.016) ( Table 4 ). In total, genetic mutations in the Ras-PI3K pathway and/or copy number losses in PTEN and/or NF1 were detected in 20 of 22 tumors (91%). The 250K SNP array also revealed LOH in both PTEN and NF1 genes in one of the six tumors.
Discussion
The relationship between CIN and MSI in endometrial carcinomas Our analyses of genomic instability revealed that most of the endometrial carcinomas possess CIN and/or MSI. The positive ratios of CIN and MSI were 84% (21/25) and 40% (10/25), respectively. Inconsistent with colorectal cancer (Choi et al., 2002) , coexistence of MSIhigh and positive CIN was observed in 28% (7/25) of our samples, especially in CIN-intermediate tumors (6/14 ¼ 43%). This overlap might be explained, at least in part, by the detection of CNN LOH, as described below. The ratio of MSI-high (40%) in this study was higher than that (15-20%) in previous reports (Atkin, 2001; Woerner et al., 2003) , presumably because all the tumors in this study are endometrioid adenocarcinomas. In spite of correlation with lymphovascular invasion, MSI-high showed a trend of favorable prognosis. Positive MSI was also reported to correlate with advanced stage and deep myometrial invasion in endometrial carcinomas (Black et al., 2006) . On the other hand, we showed that CIN-extensive was an independent poor prognostic factor, without any significant associations with clinicopathological factors. These data suggest that the aggressive phenotype of CIN-extensive tumors is not predicted by any clinicopathological characteristics, and the favorable prognosis in MSI-high tumors might be explained by the inverse trend between MSI and CIN status. In this analysis, we added SNP array data from 11 specimens with only tumor DNA, in addition to 31 specimens with both tumor and normal DNA. We confirmed that the presence of CNN LOH affected the classification (CIN-extensive versus others) only in one of the 31 specimens with paired DNA. An additional 10 specimens classified by array CGH also supported the poor prognostic effect of CIN-extensive (data not shown). Therefore, our CIN classification would be also applicable to the data of either SNP array without normal DNA or array CGH. Although the SNP typing Genome-wide SNP arrays in endometrial carcinomas S Murayama-Hosokawa et al array or array CGH may not be currently cost-effective, defining CIN status will become more feasible with the prevalence of genome-wide analysis of each cancer. The information that all the patients with risk factors (such as lymph node metastasis and deep myometrial invasion) received adjuvant radiation and/or chemotherapy suggests that CIN-extensive might be also associated with sensitivity to adjuvant chemotherapy and/or radiotherapy. The loci of copy alterations in CIN-extensive did not frequently overlap with each other in our analyses (Figure 1) . Rather, the region of copy alterations spreads to the entire genome. The numerous patterns of copy alterations in CIN-extensive tumors indicate that the degree of CIN itself, not the alterations of specific genes, might be a significant marker for tumor aggressiveness.
CNN LOH and HD in endometrial carcinomas
Recently, CNN LOH has been reported in various types of tumors at the loci of important genes that drive the carcinogenic process (Bacolod et al., 2009; Tuna et al., 2009 ). The ratio of CNN LOH was reported at 20-50% in several tumors, including leukemia, liver cancer and ovarian cancer Midorikawa et al., 2006; Dunbar et al., 2008; Walsh et al., 2008) . Considering the fact that only 28% of tumors were CINextensive, it is noteworthy that CNN LOH was positive in 42% of endometrial carcinomas. Especially, 3 of 14 CIN-intermediate tumors show CNN LOH alone without any other chromosomal gains and losses that would be overlooked by CGH. These results suggest that CNN LOH shares a significant ratio and may have key roles in endometrial carcinogenesis. We found one HD and one CNN LOH at the CDKN2A locus (9p21.3) and two CNN LOH at the TP53 locus (17p13.1). These alterations have been reported in other types of malignancy such as of the colon, breast and leukocyte (Melcher et al., 2007; Kawamata et al., 2008; Walsh et al., 2008 Abbreviations: HD, homozygous deletion; PI3K, phosphatidylinositol 3 0 -kinase.
Genome-wide SNP arrays in endometrial carcinomas S Murayama-Hosokawa et al LOH and HD of specific tumor suppressor genes might be widespread in various types of tumors. Copy number polymorphisms are known to be common in the human genome (Conrad et al., 2006) . Normalization of tumor samples to their matching normal germline DNA is a useful method to mask such copy number polymorphisms; however, copy number polymorphisms and interchromosomal segmental duplications can still masquerade as somatic alterations in tumors with extensive copy number imbalances (Gorringe and Campbell, 2008) . In our analysis, one HD at 6q21.2 was suggested to be one of the germline CNVs. Thus, it is very important to exclude the possibility of germline CNVs in each HD region.
Biallelic PTEN inactivation and MSI status
The most frequent CNN LOH was 10q22.2-10q26.3, which includes PTEN. The ratio of LOH in PTEN has been reported to be 20-40% by microsatellite markers and approximately 15% by CGH (Sirchia et al., 2000; Suehiro et al., 2000; Toda et al., 2001; Micci et al., 2004; Levan et al., 2006) . In our analysis, four of seven LOH detected at the PTEN locus turned out to be CNN LOH, indicating that LOH of PTEN has been underestimated by CGH in endometrial carcinomas. Three of the four tumors with CNN LOH at PTEN possess homozygous PTEN mutations. In addition, HD of PTEN at 10q23 was also detected in one tumor. We previously reported multiple PTEN mutations in 9 out of 37 PTEN mutant tumors (Minaguchi et al., 2001) . Taken together, inactivation of PTEN is caused by various reasons, such as (1) a mutation and LOH without gain of the opposite allele, (2) homozygous mutations and CNN LOH, (3) HD and (4) mutations in both alleles. There might be other unknown mechanisms of biallelic PTEN inactivation, as 11 tumors showed monoallelic PTEN alterations in this study, including one tumor with CNN LOH at PTEN. PTEN mutations in endometrial carcinomas were reported to be more common in MSI-positive tumors, compared with MSS tumors (Bilbao et al., 2006) . In this study, all the three tumors with multiple PTEN mutations were MSI-high, whereas six out of seven tumors with PTEN deletion(s) were MSS. These data suggest that the mechanism of PTEN inactivation is affected by MSI status.
Prevalent genomic alterations in the Ras signaling pathway
The frequency of mutations in K-Ras, PTEN and PIK3CA in the Ras-PI3K pathway is remarkable in endometrial carcinomas. NF1, located at 17q11.2, functions as a negative regulator of the Ras signaling pathway (McCormick, 1995) . Recently, CNN LOH surrounding the NF1 locus was observed in juvenile myelomonocytic leukemia (Flotho et al., 2007) . Although inactivation of NF1 has not been reported in endometrial carcinomas, we have detected one HD at 17q11.2 and three LOH at this locus in 31 samples (13%). Copy number losses in NF1 suggest that there might be other types of alterations in this gene in endometrial carcinomas, such as inactivating mutations reported in glioblastomas (Cancer Genome Atlas Research Network, 2008) .
Amplifications of PIK3CA (3q26.3) and K-Ras (12p12.1) loci are other possible mechanisms of alterations. SNP array analysis revealed copy number gains at the locus of K-Ras (13%) and PIK3CA (13%), supporting the previous reports (Oda et al., 2005; Salvesen et al., 2009) . One of the two tumors with CNN LOH at the PIK3CA locus contains a 'hot spot' PIK3CA mutation (H1047R), which might result in increased activity of mutant p110alpha. However, it is to be elucidated whether gains (and CNN LOH without a mutation in the opposite allele) at the loci of PIK3CA and K-Ras are in fact targeting these genes. Comprehensive analyses of genomic alterations in the Ras-PI3K pathway revealed that genomic alterations in the Ras-PI3K pathway are extensively common, as observed in Table 4 . These results suggest that the activation of this pathway might be a critical step in endometrial tumorigenesis and that targeting this pathway might be a promising therapeutic strategy in endometrial carcinomas.
Materials and methods
Tumor samples and genomic DNA Surgical samples were obtained from a total of 42 patients with primary endometrial carcinomas (endometrioid adenocarcinomas) who underwent resection of their tumors at the University of Tokyo Hospital. All the 42 patients were treated as previously described (Onda et al., 1997) . Briefly, they received primary surgery, including hysterectomy, bilateral salpingo-oophorectomy and systematic lymphadenectomy. Whole-pelvis irradiation was indicated for stage I-III patients with at least one of the following factors: deep myometrial invasion, positive lymph nodes, adnexal metastases and pelvic peritoneal metastases. The stage III patients with either adnexal/peritoneal involvement or aortic node metastases were treated with three cycles of platinum-based chemotherapy before radiation therapy. Stage IV patients were treated postoperatively with five cycles of platinum-based chemotherapy. All the recurrent patients received platinum-based chemotherapy.
All of the patients provided informed consent for the research use of their samples and the collection, and the use of tissues for this study was approved by the appropriate institutional ethics committees. The fresh-frozen tumors were embedded in OCT compound, and the 4-mm tissue sections were stained with hematoxylin and eosin. We confirmed that each section contains a high purity of tumor epithelium (460%) and used those sections for DNA extraction. Genomic DNA was isolated from the tumor sections or lymphocyte pellets using a QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA), according to the manufacturer's specifications. Paired genomic DNA was also extracted as a control through blood samples in 31 out of 42 patients. The clinical status of these 42 patients was summarized in Supplementary Table 1. SNP array SNP array was performed in 31 clinical samples with paired tumor DNA and normal DNA, and 11 clinical samples with tumor DNA alone. Experimental procedures for GeneChip were performed according to GeneChip Expression Analysis Technical Manual (Affymetrix, Santa Clara, CA, USA), using a Human mapping 50K Xba I Array in 36 out of 42 samples. The remaining six samples with paired DNA were analyzed with a Human mapping 250K Nsp Array (Affymetrix).
Genome imbalance map
The GIM algorithm was applied to the raw data of endometrial cancer and peripheral blood obtained from SNP arrays. We previously reported that the purity of tumor epithelium at 50% is sufficient for the GIM algorithm (Ishikawa et al., 2005) . The basic concept of GIM involves the normalization of probe level signals, as previously described (Ishikawa et al., 2005) . Briefly, the signal intensity ratio between the raw signal intensity from the cancer and paired normal samples was calculated from the perfect match probes for each SNP locus by taking the median after omitting the highest and lowest values. Second, we calculated the adjusted ratio, which is the raw ratio divided by the expected ratio. The expected ratio is calculated by adjusting several parameters for each experiment, for example, length of Xba I (or Nsp) fragment, percentage of GC of Xba I (or Nsp) fragments, local GC content, hybridization-free energy of 25-mer probe sequences and genomic mean of signal intensity of perfect match probes from reference sample. For allele-specific copy number analysis in this GIM algorism, the relative ratio of 0.5, 1 and 1.5 theoretically corresponds to 0, 1 and 2 copies, respectively (Figure 4) . We detected allele-specific copy number alterations, using the cutoff relative ratio of 41.3 (1.6 copies) for gain and o0.7 (0.4 copies) for loss in each region. Total copy number alterations were also detected by using the cutoff relative ratio of 41.15 (2.6 copies) for gain and o0.85 (1.4 copies) for loss.
MSI analysis
Genomic DNAs extracted from the samples were used to study MSI status using five fluorescence-labeled microsatellite markers (BAT25, BAT26, D2S123, D5S346 and D17S250). Primer sequences have been previously described (Loukola et al., 2001) . PCR reactions were performed with KOD plus DNA Polymerase (TOYOBO, Osaka, Japan). The PCR conditions were as follows: 941C for 2 min; 30 cycles of 941C for 15 s, 54-601C for 30 s, 681C for 30 s, followed by a final extension at 681C for 2 min. After PCR, 1 ml of the product ( Â 30 diluted) was mixed with 10 ml Hi-di Formamide and a size marker. This product was denatured at 951C for 5 min and cooled on ice before loading onto ABI 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Results were analyzed by Genemapper Software Version 4.0 (Applied Biosystems). Determination of MSI status was made according to the presence of mutant alleles in tumor DNA compared with blood DNA. MSI status was determined as follows: tumors with two or more positive MSI markers as MSI-H, one positive MSI marker as MSI-L, and no positive MSI markers as MSS (microsatellite stable).
Mutational analysis
Mutations for PTEN (exon1-8), K-Ras (exon1 and 2) and PIK3CA (exon9 and 20) were analyzed as previously described (Minaguchi et al., 2001; Oda et al., 2005 Oda et al., , 2008 . Figure 4 Detection of allele-specific copy number alterations, including homozygous deletions (HD), using a human mapping 50K SNP array technology. Red bar corresponds to the allele with a higher copy number, and blue bar to that with a lower copy number. This representative sample shows LOH at multiple loci (top). Inside the LOH, chromosome 10q23.3 is homozygously deleted as shown in the bottom.
Statistical analysis
Genome-wide SNP arrays in endometrial carcinomas S Murayama-Hosokawa et al curves were constructed using the Kaplan-Meier method and compared with the log-rank test. The analyses were carried out using the JMP 7 statistics package (SAS Institute, Cary, NC, USA). Multivariate analysis was evaluated by Cox's proportional hazards model.
Conclusion
We comprehensively analyzed genomic alterations in endometrial carcinomas. The novel classification by the number of chromosomal imbalances revealed that CIN-extensive is an independent poor prognostic factor. As the status of genomic instability is not morphologically recognized, our CIN classification would provide a useful biomarker for prognosis in endometrial carcinomas. SNP array analysis revealed CNN LOH at 42% and HD at 10%, including the locus of PTEN.
Our data indicated that alterations in the Ras-PI3K pathway are extensively prevalent in endometrial carcinomas through both chromosomal imbalances and genetic mutations.
